# Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

> **NCT04471337** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 32 (actual)

## Conditions studied

- Endometriosis Related Pain
- Overactive Bladder
- Diabetic Neuropathic Pain
- Refractory or Unexplained Chronic Cough

## Interventions

- **DRUG:** BAY1817080

## Key facts

- **NCT ID:** NCT04471337
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-12
- **Primary completion:** 2021-02-15
- **Final completion:** 2021-05-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04471337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04471337, "Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04471337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*